Trials / Unknown
UnknownNCT03441516
Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia
Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia: A Multi-center, Randomized, Open-label, Pilot Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the performance of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) in patients with Alzheimer's disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alfoatirin® Tab. + Aripezil® Tab. | Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks |
| DRUG | Aripezil® Tab. | Donepezil 10 mg Oral Tablet qd for 24 weeks |
Timeline
- Start date
- 2018-04-19
- Primary completion
- 2019-07-04
- Completion
- 2021-12-31
- First posted
- 2018-02-22
- Last updated
- 2020-12-22
Locations
6 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03441516. Inclusion in this directory is not an endorsement.